18 results on '"Scher, Jose U."'
Search Results
2. More on Covid-19 in Immune-Mediated Inflammatory Diseases. Reply.
- Author
-
Haberman RH, Adhikari S, and Scher JU
- Subjects
- COVID-19, Humans, SARS-CoV-2, Betacoronavirus, Coronavirus Infections, Inflammation, Pandemics, Pneumonia, Viral
- Published
- 2020
- Full Text
- View/download PDF
3. Interleukin-17 Inhibition in Spondyloarthritis Is Associated With Subclinical Gut Microbiome Perturbations and a Distinctive Interleukin-25-Driven Intestinal Inflammation.
- Author
-
Manasson J, Wallach DS, Guggino G, Stapylton M, Badri MH, Solomon G, Reddy SM, Coras R, Aksenov AA, Jones DR, Girija PV, Neimann AL, Heguy A, Segal LN, Dorrestein PC, Bonneau R, Guma M, Ciccia F, Ubeda C, Clemente JC, and Scher JU
- Subjects
- Antibodies, Monoclonal, Humanized pharmacology, Arthritis, Psoriatic metabolism, Arthritis, Psoriatic microbiology, Female, Humans, Intestinal Mucosa metabolism, Intestines drug effects, Intestines microbiology, Male, Middle Aged, Spondylarthritis metabolism, Spondylarthritis microbiology, Tumor Necrosis Factor Inhibitors pharmacology, Antibodies, Monoclonal, Humanized therapeutic use, Arthritis, Psoriatic drug therapy, Gastrointestinal Microbiome drug effects, Inflammation metabolism, Interleukin-17 immunology, Spondylarthritis drug therapy, Tumor Necrosis Factor Inhibitors therapeutic use
- Abstract
Objective: To characterize the ecological effects of biologic therapies on the gut bacterial and fungal microbiome in psoriatic arthritis (PsA)/spondyloarthritis (SpA) patients., Methods: Fecal samples from PsA/SpA patients pre- and posttreatment with tumor necrosis factor inhibitors (TNFi; n = 15) or an anti-interleukin-17A monoclonal antibody inhibitor (IL-17i; n = 14) underwent sequencing (16S ribosomal RNA, internal transcribed spacer and shotgun metagenomics) and computational microbiome analysis. Fecal levels of fatty acid metabolites and cytokines/proteins implicated in PsA/SpA pathogenesis or intestinal inflammation were correlated with sequence data. Additionally, ileal biopsies obtained from SpA patients who developed clinically overt Crohn's disease (CD) after treatment with IL-17i (n = 5) were analyzed for expression of IL-23/Th17-related cytokines, IL-25/IL-17E-producing cells, and type 2 innate lymphoid cells (ILC2s)., Results: There were significant shifts in abundance of specific taxa after treatment with IL-17i compared to TNFi, particularly Clostridiales (P = 0.016) and Candida albicans (P = 0.041). These subclinical alterations correlated with changes in bacterial community co-occurrence, metabolic pathways, IL-23/Th17-related cytokines, and various fatty acids. Ileal biopsies showed that clinically overt CD was associated with expansion of IL-25/IL-17E-producing tuft cells and ILC2s (P < 0.05), compared to pre-IL-17i treatment levels., Conclusion: In a subgroup of SpA patients, the initiation of IL-17A blockade correlated with features of subclinical gut inflammation and intestinal dysbiosis of certain bacterial and fungal taxa, most notably C albicans. Further, IL-17i-related CD was associated with overexpression of IL-25/IL-17E-producing tuft cells and ILC2s. These results may help to explain the potential link between inhibition of a specific IL-17 pathway and the (sub)clinical gut inflammation observed in SpA., (© 2019, American College of Rheumatology.)
- Published
- 2020
- Full Text
- View/download PDF
4. The role of the gut microbiome in systemic inflammatory disease.
- Author
-
Clemente JC, Manasson J, and Scher JU
- Subjects
- Autoimmune Diseases immunology, Fecal Microbiota Transplantation methods, Gastrointestinal Microbiome physiology, Humans, Inflammation immunology, Inflammatory Bowel Diseases immunology, Inflammatory Bowel Diseases pathology, Microbiota, Mucous Membrane immunology, Prebiotics, Probiotics, Autoimmune Diseases microbiology, Feeding Behavior physiology, Gastrointestinal Microbiome immunology, Inflammation microbiology, Inflammatory Bowel Diseases microbiology, Mucous Membrane microbiology
- Abstract
The role of the gut microbiome in models of inflammatory and autoimmune disease is now well characterized. Renewed interest in the human microbiome and its metabolites, as well as notable advances in host mucosal immunology, has opened multiple avenues of research to potentially modulate inflammatory responses. The complexity and interdependence of these diet-microbe-metabolite-host interactions are rapidly being unraveled. Importantly, most of the progress in the field comes from new knowledge about the functional properties of these microorganisms in physiology and their effect in mucosal immunity and distal inflammation. This review summarizes the preclinical and clinical evidence on how dietary, probiotic, prebiotic, and microbiome based therapeutics affect our understanding of wellness and disease, particularly in autoimmunity., Competing Interests: Competing interests: We have read and understood the BMJ policy on declaration of interests and declare the following interests: none., (Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.)
- Published
- 2018
- Full Text
- View/download PDF
5. Alteration of the intestinal microbiome characterizes preclinical inflammatory arthritis in mice and its modulation attenuates established arthritis.
- Author
-
Rogier R, Evans-Marin H, Manasson J, van der Kraan PM, Walgreen B, Helsen MM, van den Bersselaar LA, van de Loo FA, van Lent PL, Abramson SB, van den Berg WB, Koenders MI, Scher JU, and Abdollahi-Roodsaz S
- Subjects
- Animals, Arthritis, Experimental genetics, Arthritis, Experimental immunology, Bacteroidetes genetics, Disease Models, Animal, Firmicutes genetics, Humans, Inflammation genetics, Inflammation immunology, Inflammation pathology, Mice, Proteobacteria genetics, RNA, Ribosomal, 16S genetics, Serum Amyloid A Protein metabolism, Th1 Cells immunology, Th17 Cells microbiology, Arthritis, Experimental microbiology, Gastrointestinal Microbiome genetics, Inflammation microbiology, Th17 Cells immunology
- Abstract
Perturbations of the intestinal microbiome have been observed in patients with new-onset and chronic autoimmune inflammatory arthritis. However, it is currently unknown whether these alterations precede the development of arthritis or are rather a consequence of disease. Modulation of intestinal microbiota by oral antibiotics or germ-free condition can prevent arthritis in mice. Yet, the therapeutic potential of modulation of the microbiota after the onset of arthritis is not well characterized. We here show that the intestinal microbial community undergoes marked changes in the preclinical phase of collagen induced arthritis (CIA). The abundance of the phylum Bacteroidetes, specifically families S24-7 and Bacteroidaceae was reduced, whereas Firmicutes and Proteobacteria, such as Ruminococcaceae, Lachnospiraceae and Desulfovibrinocaceae, were expanded during the immune-priming phase of arthritis. In addition, we found that the abundance of lamina propria Th17, but not Th1, cells is highly correlated with the severity of arthritis. Elimination of the intestinal microbiota during established arthritis specifically reduced intestinal Th17 cells and attenuated arthritis. These effects were associated with reduced serum amyloid A expression in ileum and synovial tissue. Our observations suggest that intestinal microbiota perturbations precede arthritis, and that modulation of the intestinal microbiota after the onset of arthritis may offer therapeutic opportunities.
- Published
- 2017
- Full Text
- View/download PDF
6. Microbiome and mucosal inflammation as extra-articular triggers for rheumatoid arthritis and autoimmunity.
- Author
-
Brusca SB, Abramson SB, and Scher JU
- Subjects
- Animals, Antigens, Bacterial immunology, Arthritis, Experimental immunology, Arthritis, Experimental microbiology, Arthritis, Rheumatoid immunology, Arthritis, Rheumatoid microbiology, Autoimmunity immunology, Disease Models, Animal, Dysbiosis complications, Dysbiosis immunology, Humans, Inflammation immunology, Mice, Mucous Membrane immunology, Mucous Membrane microbiology, Periodontal Diseases complications, Periodontal Diseases immunology, Arthritis, Rheumatoid etiology, Inflammation complications, Microbiota
- Abstract
Purpose of Review: Despite the progress toward understanding the molecular pathogenesis of rheumatoid arthritis (RA), its cause remains elusive. Genes are important but rather insufficient to explain the majority of RA cases. This review describes the novel data supporting the microbiome and its interactions with the human host as potential en('in')vironmental factors in RA pathogenesis., Recent Findings: Animal models of inflammatory arthritis have shown that the presence of bacteria in mucosal surfaces is sufficient to alter local and systemic host immune responses and elicit joint inflammation. Human RA studies have focused on three mucosal sites: the gut, the gingiva, and the respiratory tree. The oral microbiome, and specifically Porphyromonas gingivalis, has long been implicated. Novel sequencing technologies have allowed investigations into the role of the gut microbiome in the development of autoimmune arthritis. Most recently, the pulmonary parenchyma has also been described as yet another possible mucosal site of initiation of autoimmunity in RA., Summary: Emerging data implicate the microbiome in RA pathogenesis. Mucosal sites exposed to a high load of bacterial antigens--such as the periodontium, lung, and gut--may represent the initial site of autoimmune generation. If validated, these findings could lead to the discovery of potential biomarkers and therapeutic approaches in the preclinical and clinical phases of RA.
- Published
- 2014
- Full Text
- View/download PDF
7. KLK6 expression in skin induces PAR1-mediated psoriasiform dermatitis and inflammatory joint disease
- Author
-
Billi, Allison C., Ludwig, Jessica E., Fritz, Yi, Rozic, Richard, Swindell, William R., Tsoi, Lam C., Gruzska, Dennis, Abdollahi-Roodsaz, Shahla, Xing, Xianying, Diaconu, Doina, Uppala, Ranjitha, Camhi, Maya I., Klenotic, Philip A., Sarkar, Mrinal K., Husni, M. Elaine, Scher, Jose U., McDonald, Christine, Kahlenberg, J. Michelle, Midura, Ronald J., Gudjonsson, Johann E., and Ward, Nicole L.
- Subjects
Kallikrein ,Inflammation ,Dermatologic agents ,Vorapaxar ,Psoriasis ,Skin ,Drug approval ,Arthritis ,Dermatitis ,Health care industry - Abstract
Kallikrein-related peptidase 6 (KLK6) is a secreted serine protease hypothesized to promote inflammation via cleavage of protease-activated receptor 1 (PAR1) and PAR2. KLK6 levels are elevated in multiple inflammatory and autoimmune conditions, but no definitive role in pathogenesis has been established. Here, we show that skin-targeted overexpression of KLK6 causes generalized, severe psoriasiform dermatitis with spontaneous development of debilitating psoriatic arthritis-like joint disease. The psoriatic skin and joint phenotypes are reversed by normalization of skin KLK6 levels and attenuated following genetic elimination of PAR1 but not PAR2. Conservation of this regulatory pathway was confirmed in human psoriasis using vorapaxar, an FDA-approved PAR1 antagonist, on explanted lesional skin from patients with psoriasis. Beyond defining a critical role for KLK6/PAR1 signaling in promoting psoriasis, our results demonstrate that KLK6/PAR1-mediated inflammation in the skin alone is sufficient to drive inflammatory joint disease. Further, we identify PAR1 as a promising cytokine-independent target in therapy of psoriasis and psoriatic arthritis., Introduction Psoriasis is a chronic, incurable systemic inflammatory disease with complex and incompletely understood pathogenesis. Two percent to 3% of the population worldwide suffers from psoriasis, and affected individuals show [...]
- Published
- 2020
- Full Text
- View/download PDF
8. CCL20 in psoriasis: A potential biomarker of disease severity, inflammation, and impaired vascular health.
- Author
-
Elnabawi, Youssef A., Garshick, Michael S., Tawil, Michael, Barrett, Tessa J., Fisher, Edward A., Lo Sicco, Kristen, Neimann, Andrea L., Scher, Jose U., Krueger, James, and Berger, Jeffrey S.
- Abstract
Background: Psoriasis is associated with increased cardiovascular risk that is not captured by traditional proinflammatory biomarkers.Objective: To investigate the relationship between Psoriasis Area and Severity Index, circulating proinflammatory biomarkers, and vascular health in psoriasis.Methods: In patients with psoriasis and in age and sex-matched controls, 273 proteins were analyzed with the Proseek Multiplex Cardiovascular disease reagents kit and Inflammatory reagents kit (Olink Bioscience), whereas vascular endothelial inflammation and health were measured via direct transcriptomic analysis of brachial vein endothelial cells.Results: In psoriasis, chemokine ligand 20 (CCL20), interleukin (IL) 6, and IL-17A were the top 3 circulating proinflammatory cytokines. Vascular endothelial inflammation correlated with CCL20 (r = 0.55; P < .001) and less so with IL-6 (r = 0.36; P = .04) and IL-17A (r = 0.29; P = .12). After adjustment for potential confounders, the association between CCL20 and vascular endothelial inflammation remained significant (β = 1.71; P = .02). In nested models, CCL20 added value (χ2 = 79.22; P < .001) to a model already incorporating the Psoriasis Area and Severity Index, Framingham risk, high-sensitivity C-reactive protein, Il-17A, and IL-6 (χ2 = 48.18; P < .001) in predicting vascular endothelial inflammation.Limitations: Our study was observational and did not allow for causal inference in the relationship between CCL20 and cardiovascular risk.Conclusion: We demonstrate that CCL20 expression has a strong association with vascular endothelial inflammation, reflects systemic inflammation, and may serve as a potential biomarker of impaired vascular health in psoriasis. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
9. COVID‐19 in Patients With Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and Disease‐Modifying Antirheumatic Drugs on Clinical Outcomes.
- Author
-
Haberman, Rebecca H., Castillo, Rochelle, Chen, Alan, Yan, Di, Ramirez, Deborah, Sekar, Vaish, Lesser, Robert, Solomon, Gary, Neimann, Andrea L., Blank, Rebecca B., Izmirly, Peter, Webster, Dan E., Ogdie, Alexis, Troxel, Andrea B., Adhikari, Samrachana, and Scher, Jose U.
- Subjects
ARTHRITIS diagnosis ,HOSPITAL care ,IMMUNOSUPPRESSIVE agents ,INFLAMMATION ,LONGITUDINAL method ,MORTALITY ,REGRESSION analysis ,COMORBIDITY ,TREATMENT effectiveness ,DATA analysis software ,DESCRIPTIVE statistics ,COVID-19 - Abstract
Objective: To characterize the hospitalization and death rates among patients with inflammatory arthritis (IA) affected by coronavirus disease 2019 (COVID‐19) and to analyze the associations of comorbidities and immunomodulatory medications with infection outcomes. Methods: Data on clinical and demographic features, maintenance treatment, disease course, and outcomes in individuals with IA (rheumatoid arthritis and spondyloarthritis) with symptomatic COVID‐19 infection were prospectively assessed via web‐based questionnaire followed by individual phone calls and electronic medical record review. Baseline characteristics and medication use were summarized for hospitalized and ambulatory patients, and outcomes with the different medication classes were compared using multivariable logistic regression. Results: A total of 103 patients with IA were included in the study (80 with confirmed COVID‐19 and 23 with high suspicion of COVID‐19). Hospitalization was required in 26% of the participants, and 4% died. Patients who were hospitalized were significantly more likely to be older (P < 0.001) and have comorbid hypertension (P = 0.001) and chronic obstructive pulmonary disease (P = 0.02). IA patients taking oral glucocorticoids had an increased likelihood of being admitted for COVID‐19 (P < 0.001), while those receiving maintenance anticytokine biologic therapies did not. Conclusion: Among patients with underlying IA, COVID‐19 outcomes were worse in those receiving glucocorticoids but not in patients receiving maintenance anticytokine therapy. Further work is needed to understand whether immunomodulatory therapies affect COVID‐19 incidence. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
10. Interleukin 1 receptor antagonist ( ) gene variants predict radiographic severity of knee osteoarthritis and risk of incident disease.
- Author
-
Attur, Mukundan, Hua Zhou, Samuels, Johathan, Krasnokutsky, Svetlana, Yau, Michelle, Scher, Jose U., Doherty, Michael, Wilson, Anthony G., Bencardino, Jenny, Hochberg, Marc, Jordan, Joanne M., Mitchell, Braxton, Kraus, Virginia B., Abramson, Steven B., and Zhou, Hua
- Subjects
KNEE diseases ,PROTEINS ,RESEARCH ,RESEARCH methodology ,GENETIC polymorphisms ,RADIOGRAPHY ,CASE-control method ,EVALUATION research ,MEDICAL cooperation ,SEVERITY of illness index ,RISK assessment ,COMPARATIVE studies ,RHEUMATOID arthritis ,OSTEOARTHRITIS ,HAPLOTYPES ,RESEARCH funding ,KNEE - Abstract
Objective: In these studies, we examined the association of single nucleotide polymorphisms (SNPs) of the IL1RN gene with radiographic severity of symptomatic knee osteoarthritis (SKOA) and the risk of incident OA. We also explored these genetic polymorphisms in patients with new onset rheumatoid arthritis (RA).Methods: Over 1000 subjects who met American College of Rheumatology criteria for tibiofemoral OA were selected from three independent, National Institute of Health (NIH)-funded cohorts. CTA and TTG haplotypes formed from three SNPs of the IL1RN gene (rs419598, rs315952, rs9005) were assessed for association with radiographic severity, and risk for incident radiographic OA (rOA) in a nested case-control cohort. These IL1RN haplotypes were also assessed for association with disease activity (DAS28) and plasma inflammatory markers in patients with RA.Results: Carriage of the IL1RN TTG haplotype was associated with increased odds of more severe rOA compared with age-matched, sex-matched and body mass index-matched individuals. Examination of the osteoarthritis initiative Incidence Subcohort demonstrated that carriage of the TTG haplotype was associated with 4.1-fold (p=0.001) increased odds of incident rOA. Plasma IL-1Ra levels were lower in TTG carriers, while chondrocytes from TTG carriers exhibited decreased secretion of IL-1Ra. In patients with RA, the TTG haplotype was associated with increased DAS28, decreased plasma IL-1Ra and elevations of plasma inflammatory markers (hsCRP, interleukin 6 (IL-6)).Conclusion: Carriage of the IL1RN TTG haplotype is associated with more severe rOA, increased risk for incident OA, and increased evidence of inflammation in RA. These data suggest that the IL1RN TTG risk haplotype, associated with decreased IL-1Ra plasma levels, impairs endogenous 'anti-inflammatory' mechanisms. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
11. Microbiota‐Dependent Involvement of Th17 Cells in Murine Models of Inflammatory Arthritis.
- Author
-
Evans‐Marin, Heather, Rogier, Rebecca, Koralov, Sergei B., Manasson, Julia, Roeleveld, Debbie, Kraan, Peter M., Scher, Jose U., Koenders, Marije I., and Abdollahi‐Roodsaz, Shahla
- Subjects
ANIMAL experimentation ,ARTHRITIS ,COLLAGEN ,CYTOKINES ,FLOW cytometry ,GRANULOCYTE-macrophage colony-stimulating factor ,INFLAMMATION ,INTERLEUKINS ,MICE ,T cells ,TUMOR necrosis factors ,GUT microbiome ,TREATMENT effectiveness - Abstract
Objective: Intestinal microbiota are associated with the development of inflammatory arthritis. The aim of this study was to dissect intestinal mucosal immune responses in the preclinical phase of arthritis and determine whether the presence of Th17 cells, beyond involvement of the cytokine interleukin‐17 (IL‐17), is required for arthritis development, and whether the involvement of Th17 cells in arthritis depends on the composition of the host microbiota. Methods: Mucosal T cell production of IL‐17, interferon‐γ, tumor necrosis factor α (TNFα), IL‐22, and granulocyte–macrophage colony‐stimulating factor (GM‐CSF) was analyzed by flow cytometry and Luminex assay before arthritis onset in mice immunized to develop collagen‐induced arthritis (CIA). Pathogenic features of arthritis in mice with CIA and mice with antigen‐induced arthritis were compared between Th17 cell–deficient (CD4‐Cre+Rorcflox/flox) and Th17 cell–sufficient (CD4‐Cre−Rorcflox/flox) mice. In addition, the impact of intestinal microbiota on the Th17 cell dependence of CIA was assessed. Results: Lamina propria CD4 T cells were activated before the onset of arthritis in mice with CIA, with marked up‐regulation of several cytokines, including IL‐17A, TNFα, and GM‐CSF. CD4‐Cre+Rorcflox/flox mice showed a specific reduction in intestinal mucosal levels of Th17 cells and partially reduced levels of IL‐17–producing CD8 T cells. However, total levels of IL‐17A, mostly produced by γδ T cells and neutrophils, were unaffected. The severity of arthritis was significantly reduced in Th17 cell–deficient mice, suggesting that Th17 cells have additional, IL‐17A–independent roles in inflammatory arthritis. Accordingly, antigen‐stimulated T cells from Th17 cell–deficient mice produced less IL‐17A, IL‐17F, and GM‐CSF. Importantly, the dependence of CIA on the involvement of Th17 cells was mitigated in the presence of an alternative microbiome. Conclusion: These data from murine models suggest that activation of mucosal immunity precedes the development of arthritis, and also that Th17 cells have a microbiota‐dependent role in arthritis. Therefore, a microbiome‐guided stratification of patients might improve the efficacy of Th17‐targeted therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
12. Decreased Bacterial Diversity Characterizes the Altered Gut Microbiota in Patients With Psoriatic Arthritis, Resembling Dysbiosis in Inflammatory Bowel Disease.
- Author
-
Scher, Jose U., Ubeda, Carles, Artacho, Alejandro, Attur, Mukundan, Isaac, Sandrine, Reddy, Soumya M., Marmon, Shoshana, Neimann, Andrea, Brusca, Samuel, Patel, Tejas, Manasson, Julia, Pamer, Eric G., Littman, Dan R., and Abramson, Steven B.
- Subjects
- *
TRANSPLANTATION of organs, tissues, etc. , *ANALYSIS of variance , *CHI-squared test , *GASTROINTESTINAL diseases , *INFLAMMATION , *MICROBIOLOGY , *PSORIASIS , *PSORIATIC arthritis , *RESEARCH funding , *STATISTICS , *T-test (Statistics) , *HLA-B27 antigen , *GENOMICS , *DATA analysis , *DATA analysis software , *DESCRIPTIVE statistics , *MANN Whitney U Test ,IMMUNE system physiology - Abstract
Objective To characterize the diversity and taxonomic relative abundance of the gut microbiota in patients with never-treated, recent-onset psoriatic arthritis (PsA). Methods High-throughput 16S ribosomal RNA pyrosequencing was utilized to compare the community composition of gut microbiota in patients with PsA (n = 16), patients with psoriasis of the skin (n = 15), and healthy, matched control subjects (n = 17). Samples were further assessed for the presence and levels of fecal and serum secretory IgA (sIgA), proinflammatory proteins, and fatty acids. Results The gut microbiota observed in patients with PsA and patients with skin psoriasis was less diverse when compared to that in healthy controls. This could be attributed to the reduced presence of several taxa. Samples from both patient groups showed a relative decrease in abundance of Coprococcus species, while samples from PsA patients were also characterized by a significant reduction in Akkermansia, Ruminococcus, and Pseudobutyrivibrio. Supernatants of fecal samples from PsA patients revealed an increase in sIgA levels and decrease in RANKL levels. Analysis of fatty acids revealed low fecal quantities of hexanoate and heptanoate in both patients with PsA and patients with psoriasis. Conclusion Patients with PsA and patients with skin psoriasis had a lower relative abundance of multiple intestinal bacteria. Although some genera were concomitantly decreased in both conditions, PsA samples had a lower abundance of reportedly beneficial taxa. This gut microbiota profile in PsA was similar to that previously described in patients with inflammatory bowel disease and was associated with changes in specific inflammatory proteins unique to this group, and distinct from that in patients with skin psoriasis and healthy controls. Thus, the role of the gut microbiome in the continuum of psoriasis-PsA pathogenesis and the associated immune response merits further study. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
13. The Anti-Inflammatory Effects of Prostaglandins.
- Author
-
Scher, Jose U. and Pillinger, Michael H.
- Abstract
Long regarded as proinflammatory molecules, prostaglandins (PGs) also have anti-inflammatory effects. Both prostaglandin D
2 (PGD2 ) and its dehydration end product 15-deoxy-Δ12,14 -prostaglandin J2 (15d-PGJ2 ) seem to play important roles in regulating inflammation, via both receptor-dependent (DP1 and DP2 receptors) and receptor-independent mechanisms. Intracellular effects of PGD2 and 15d-PGJ2 that may suppress inflammation include inhibition of nuclear factor-κB (NF-κB) by multiple mechanisms (IκB kinase inhibition and blockade of NF-κB nuclear binding) and activation of peroxisome proliferator-activated receptor-γ (PPAR-γ). Prostaglandin F2α (PGF2α ) may also have important anti-inflammatory effects, although current data are limited. In animal models, expression of both PGD and PGF synthases declines during acute inflammation, only to rise again during the resolution phase, suggesting their possible role in resolving inflammation. Prostaglandin E2 (PGE2 ), the classic model of a proinflammatory lipid mediator, also has anti-inflammatory effects that are both potent and context dependent. Thus, accumulating data suggest that PGs not only participate in initiation, but may also actively contribute to the resolution of inflammation. Indeed, classic inhibitors of PG synthesis such as nonselective and cyclooxygenase-2 (COX-2) selective inhibitors (nonsteroidal anti-inflammatory drugs) may actually prolong inflammation when administered during the resolution phase. These effects may regulate not only tissue inflammation but also vascular disease, possibly shedding light on the controversy surrounding nonsteroidal anti-inflammatory drug use and its relation to myocardial infarction. In this review, we summarize the current understanding of PGs as dichotomous molecules in the inflammatory process. [ABSTRACT FROM AUTHOR]- Published
- 2009
- Full Text
- View/download PDF
14. 15d-PGJ2: The anti-inflammatory prostaglandin?
- Author
-
Scher, Jose U. and Pillinger, Michael H.
- Subjects
- *
PROSTAGLANDINS , *INFLAMMATORY mediators , *PROSTANOIDS , *LIFE sciences - Abstract
Abstract: 15-Deoxy-Δ-12,14-prostaglandin J2 (15d-PGJ2) is the most recently discovered prostaglandin. This cyclopentanone, the dehydration end product of PGD2, differs from other prostaglandins in several respects. There is no specific prostaglandin synthase (PGS) leading to 15d-PGJ2 production and no specific 15d-PGJ2 receptor has been identified to date. Instead, 15d-PGJ2 has been shown to act via PGD2 receptors (DP1 and DP2) and through interaction with intracellular targets. In particular, 15d-PGJ2 is recognized as the endogenous ligand for the intranuclear receptor PPARγ. This property is responsible for many of the 15d-PGJ2 anti-inflammatory functions. In this review, we summarize the current understanding of 15d-PGJ2 synthesis, biology and main effects both in molecular physiology and pathological states. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
15. NSAIDs retain position as first-line OA treatment.
- Author
-
Scher, Jose U. and Pillinger, Michael H.
- Subjects
- *
NONSTEROIDAL anti-inflammatory agents , *OSTEOARTHRITIS , *THERAPEUTICS , *TOXICITY testing , *PAIN , *INFLAMMATION , *PATIENTS - Abstract
The article discusses the roles of nonsteroidal anti-inflammatory drugs (NSAID) and COX-2 inhibitors in treating patients with osteoarthritis (OA). The author said that with the limited efficacy or possible toxicity of current OA treatments, traditional NSAID remain first-line therapy for patients with moderate to severe OA. NSAID minimize both pain and inflammation. These are some of the most commonly used medications in the U.S.
- Published
- 2007
16. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis
- Author
-
Scher, Jose U, Sczesnak, Andrew, Longman, Randy S, Segata, Nicola, Ubeda, Carles, Bielski, Craig, Rostron, Tim, Cerundolo, Vincenzo, Pamer, Eric G, Abramson, Steven B, Huttenhower, Curtis, and Littman, Dan R
- Subjects
microbiome ,inflammation ,autoimmunity ,metagenomics ,rheumatoid ,arthritis ,Human ,Mouse - Abstract
Rheumatoid arthritis (RA) is a prevalent systemic autoimmune disease, caused by a combination of genetic and environmental factors. Animal models suggest a role for intestinal bacteria in supporting the systemic immune response required for joint inflammation. Here we performed 16S sequencing on 114 stool samples from rheumatoid arthritis patients and controls, and shotgun sequencing on a subset of 44 such samples. We identified the presence of Prevotella copri as strongly correlated with disease in new-onset untreated rheumatoid arthritis (NORA) patients. Increases in Prevotella abundance correlated with a reduction in Bacteroides and a loss of reportedly beneficial microbes in NORA subjects. We also identified unique Prevotella genes that correlated with disease. Further, colonization of mice revealed the ability of P. copri to dominate the intestinal microbiota and resulted in an increased sensitivity to chemically induced colitis. This work identifies a potential role for P. copri in the pathogenesis of RA. DOI: http://dx.doi.org/10.7554/eLife.01202.001
- Published
- 2013
- Full Text
- View/download PDF
17. The metabolic role of the gut microbiota in health and rheumatic disease: mechanisms and interventions.
- Author
-
Abdollahi-Roodsaz, Shahla, Abramson, Steven B., and Scher, Jose U.
- Subjects
- *
GUT microbiome , *RHEUMATISM , *AUTOIMMUNE diseases , *INFLAMMATION , *ANIMAL models in research , *POLYSACCHARIDES , *DRUG therapy for rheumatism , *ANTIRHEUMATIC agents , *DIET , *PROBIOTICS , *PREBIOTICS , *SHORT-chain fatty acids - Abstract
The role of the gut microbiome in animal models of inflammatory and autoimmune disease is now well established. The human gut microbiome is currently being studied as a potential modulator of the immune response in rheumatic disorders. However, the vastness and complexity of this host-microorganism interaction is likely to go well beyond taxonomic, correlative observations. In fact, most advances in the field relate to the functional and metabolic capabilities of these microorganisms and their influence on mucosal immunity and systemic inflammation. An intricate relationship between the microbiome and the diet of the host is now fully recognized, with the microbiota having an important role in the degradation of polysaccharides into active metabolites. This Review summarizes the current knowledge on the metabolic role of the microbiota in health and rheumatic disease, including the advances in pharmacomicrobiomics and its potential use in diagnostics, therapeutics and personalized medicine. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
18. Metabolic coordination between skin epithelium and type 17 immunity sustains chronic skin inflammation.
- Author
-
Subudhi, Ipsita, Konieczny, Piotr, Prystupa, Aleksandr, Castillo, Rochelle L., Sze-Tu, Erica, Xing, Yue, Rosenblum, Daniel, Reznikov, Ilana, Sidhu, Ikjot, Loomis, Cynthia, Lu, Catherine P., Anandasabapathy, Niroshana, Suárez-Fariñas, Mayte, Gudjonsson, Johann E., Tsirigos, Aristotelis, Scher, Jose U., and Naik, Shruti
- Subjects
- *
SKIN inflammation , *LACTATES , *EPITHELIUM , *GLUCOSE transporters , *GLYCOLYSIS , *HYPOXIA-inducible factors - Abstract
Inflammatory epithelial diseases are spurred by the concomitant dysregulation of immune and epithelial cells. How these two dysregulated cellular compartments simultaneously sustain their heightened metabolic demands is unclear. Single-cell and spatial transcriptomics (ST), along with immunofluorescence, revealed that hypoxia-inducible factor 1α (HIF1α), downstream of IL-17 signaling, drove psoriatic epithelial remodeling. Blocking HIF1α in human psoriatic lesions ex vivo impaired glycolysis and phenocopied anti-IL-17 therapy. In a murine model of skin inflammation, epidermal-specific loss of HIF1α or its target gene, glucose transporter 1, ameliorated epidermal, immune, vascular, and neuronal pathology. Mechanistically, glycolysis autonomously fueled epithelial pathology and enhanced lactate production, which augmented the γδ T17 cell response. RORγt-driven genetic deletion or pharmacological inhibition of either lactate-producing enzymes or lactate transporters attenuated epithelial pathology and IL-17A expression in vivo. Our findings identify a metabolic hierarchy between epithelial and immune compartments and the consequent coordination of metabolic processes that sustain inflammatory disease. [Display omitted] • HIF1α is activated in psoriatic epidermis and associated with IL-17A • Ablating epithelial HIF1α curbs vascular, nervous, and immune skin pathology • HIF1α-induced epithelial glycolysis directs multisystemic skin pathology • Lactate, a glycolysis byproduct, potentiates the underlying γδ T17 response How immune and epithelial cells simultaneously fuel their dysfunction in chronic skin diseases is unclear. Subudhi and Konieczny et al. find that IL-17-induced epithelial HIF1α activates glycolysis, which potentiates the γδ T17 response via lactate. This metabolic circuit drives multisystems pathology and can be targeted in inflammatory disease. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.